Related Experiment Videos
The National Cancer Data Base report on soft tissue sarcoma
R E Pollock1, L H Karnell, H R Menck
1Department of Surgical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA.
Cancer
|November 15, 1996
Summary
Multimodality treatment planning for soft tissue sarcoma patients, combining surgery, radiation, and chemotherapy, is crucial. This approach aims to improve survival rates and quality of life for patients with advanced disease.
Area of Science:
- Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Soft tissue sarcoma patient survivorship and quality of life have improved over 20 years, with a 5-year survival rate around 50%.
- Treatment has evolved from single-modality surgery to limb-salvage strategies combined with radiation and chemotherapy.
Purpose of the Study:
- To identify patterns in soft tissue sarcoma treatment and patient outcomes.
- To analyze treatment modalities based on histology and anatomic site.
Main Methods:
- Analysis of soft tissue sarcoma cases diagnosed in 1988 and 1993 from the National Cancer Data Base.
- Categorization of cases by histology and anatomic site.
Main Results:
- An increase in pleural sarcomas and mesotheliomas was observed.
- A trend towards more advanced disease presentation was noted.
- While limb-sparing surgery is standard, Stage II and III patients may be undertreated due to insufficient multimodality therapy.
Conclusions:
- Pretreatment multimodality planning conferences can enhance the use of appropriate treatment combinations.
- Adopting multimodality approaches is expected to improve overall and disease-free survival rates for soft tissue sarcoma patients.